Discover

CAR
Avis Budget Group, Inc.
112.65
1 x 107.51
1 x 117.85
bid
ask
+
4.67
4.32%
1 @ 04:00 PM
113.06 +0.41 (0.36%)
Ytd-12.21%
1y-24.10%
108.73
day range
114.25
85.96
52 week range
847.70
Open108.73Prev Close107.98Low108.73High114.25Mkt Cap3.98B
Vol439.48KAvg Vol423.16KEPS-18.13P/EN/AForward P/E18.63
Beta2.11Short Ratio14.16Inst. Own118.75%DividendN/ADiv YieldN/A
Ex Div Date12-14Earning10-2750-d Avg130.65200-d Avg155.841yr Est128.57

CAR News

benzinga.com
Avis Budget Group Was Paid $650M Cash Settlement On October 5, 2026; Settlement Payment Approved By

On October 5, 2026, Avis Budget Group, Inc. (the "Company") was paid a settlement amount of

Hertz Rebounds 16% From a Record Low; Avis Climbs 5%, Ryder Ticks Up
247wallst.com
Hertz Rebounds 16% From a Record Low; Avis Climbs 5%, Ryder Ticks Up

Beaten-down rental stocks are bouncing while the wider transportation sector slips, and Hertz Global

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
prnewswire.com
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Cl

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatm

Can Higher Fleet Utilization Boost Avis Budget's Profitability?
zacks.com
Can Higher Fleet Utilization Boost Avis Budget's Profitability?

CAR's stronger utilization and lower fleet costs lift second-quarter profits despite fewer vehicles

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
globenewswire.com
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innova

Annual program will award funding to early-career healthcare professionals advancing research, educa

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
prnewswire.com
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CA

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limitin

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer
globenewswire.com
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for O

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
benzinga.com
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

U.S. stocks rose as oil fell; Benzinga highlights top analysts’ latest calls on IES Holdings, Targa

benzinga.com
Morgan Stanley Maintains Equal-Weight on Avis Budget Gr, Lowers Price Target to $95

Morgan Stanley analyst Andrew Percoco maintains Avis Budget Gr (NASDAQ:CAR) with a Equal-Weight a